首页> 美国卫生研究院文献>Clinics in Colon and Rectal Surgery >Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management
【2h】

Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management

机译:大结直肠手术的围手术期评估和优化:药物管理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The colorectal surgeon is often faced with medications that can be challenging to manage in the perioperative period. In the era of novel agents for anticoagulation and immunotherapies for inflammatory bowel disease and malignancy, understanding how to advise patients about these medications has become increasingly complex. Here, we aim to provide clarity regarding the use of these agents and their perioperative management, with a particular focus on when to stop and restart them perioperatively. This review will begin with the management of both nonbiologic and biologic therapies used in the treatment of inflammatory bowel disease and malignancy. Then, discussion will shift to anticoagulant and antiplatelet medications, including their associated reversal agents. Upon finishing this review, the reader will have gained an increased familiarity with the management of common medications requiring modification by colorectal surgeons in the perioperative period.
机译:结直肠外科医生经常面临在围手术期难以管理的药物。在炎症性肠病和恶性肿瘤的新型抗凝和免疫疗法的时代,了解如何向患者提供这些药物的建议变得越来越复杂。在这里,我们旨在明确这些药物的使用及其围手术期管理,特别关注何时在围手术期停止和重新启动它们。本综述将从用于治疗炎症性肠病和恶性肿瘤的非生物和生物疗法的管理开始。然后,讨论将转向抗凝和抗血小板药物,包括其相关的逆转药物。完成这篇综述后,读者将更加熟悉围手术期需要结直肠外科医生修改的常见药物的管理。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号